A Phase 1/1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 436 as Monotherapy and in Combination With Other Therapies in Participants With Microsatellite Instability-high (MSI-H)/Mismatch Repair Deficient (dMMR) Solid Tumors
Latest Information Update: 17 Feb 2026
At a glance
- Drugs AMG 436 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Amgen
Most Recent Events
- 17 Feb 2026 New trial record